

LEESGGGLVQPGGSMK biochemical

LEESGGGLVQPGGSMK

CATALOG #
AAA228104


PRODUCT SYNONYMS

LEESGGGLVQPGGSMK; LEESGGGLVQPGGSMK biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2096980-79-7
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	The anti-TNF antibodies blocking the action of TNF alpha revolutionized therapy of TNF-related diseases such as Inflammatory Bowel Disease, lupus, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis. By neutralizing TNF activity, anti-TNF antibodies promote mucosal healing and induce long-term remissions in vivo. The main anti-TNF antibodies that are currently authorized encompass Infliximab, Etanercept, Adalimumab, Certolizumab and Golimumab[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
DGK-IN-1, CAS 2407892-34-4



Structure
DGK-IN-1, CAS 2407892-34-4

ADDITIONAL INFORMATION

Related Product Information for LEESGGGLVQPGGSMK biochemical	LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-alpha.
References	1. WO2020006018A1

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

